Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
Patients interested in GLP-1 therapy can begin with an online intake and provider review
Women with Lipedema have unique metabolic, digestive, and inflammatory patterns, and medication dosing must be carefully tailored
Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends
Fish species rich in omega-3 fatty acidssuch as salmon, mackerel, and sardinesprovide dual benefits: they stimulate GLP-1 release while reducing systemic inflammation linked to obesity and metabolic dysfunction
An international clinical trial, called FLOW, showed the risk of kidneys significantly deteriorating or failing was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection